Trailblazer clinical trial featured in New York Times
In the narrow window in which patients are aware of their disease, they have sought help in clinical trials. But enrolling enough participants to make these trials count is not easy.
Trailblazer clinical trial featured in New England Journal of Medicine
In patients with early Alzheimer’s disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks, although results for secondary outcomes were mixed.
Lilly’s Donanemab Slows Clinical Decline of Alzheimer’s Disease
Donanemab, an investigational antibody that targets a modified form of beta amyloid, showed significant slowing of decline in cognition and daily function.
Missing bill payments could be an early sign of dementia
Alzheimer’s disease and related dementias were associated with adverse financial events starting years prior to clinical diagnosis.
ANA Presentation at CTAD 2020
The Clinical Research Center staff presented their findings at the 13th Clinical Trials on Alzheimer’s Disease Conference.
Dr. Weisman interviewed on Senior Advocates, Who’s Who
Dr. Weisman discusses COVID-19, Alzheimer’s disease, and clinical research with Jerry Rothkoff.
A New Treatment for Migraine
Thanks to the latest research, we can now target specific migraine pathways.
Infusions Explained
Infusion therapy may seem modern, but its origins trace as far back as 1492.
Dr. Weisman interviewed in Neurology Insights
Dr. Weisman has been interviewed in a new article in Neurology Insights regarding the unique challenges faced by Alzheimer’s patients and caregivers during the pandemic.
How ANA is keeping you safe
Your health is our top priority and we want to ensure that you are accessing — and not delaying — the care you need.
